Josh Schimmer is a senior managing director on Evercore ISI’s Biotech Team, focusing on small-, mid- and select large-cap biotechnology companies. In 2021, he was again ranked No. 1 in Institutional Investor’s All America Research Team for SMID biotech, a position he has maintained since 2018. He was runner-up in 2015 and 2016.
Dr. Schimmer, who has more than 15 years of biotechnology research experience, previously worked at Piper Jaffray, Lazard Capital Markets, Leerink Partners, and Cowen & Co. In addition, he spent two years on the buy-side at Davidson Kempner.
Dr. Schimmer received his M.D. and subspeciality training in internal medicine and rheumatology from the University of Toronto and earned an MBA from Harvard Business School.